UBS AG lowered shares of Selecta Biosciences, Inc. (NASDAQ:SELB) from a buy rating to a neutral rating in a research note issued to investors on Thursday morning, The Fly reports.

SELB has been the topic of several other reports. Canaccord Genuity set a $25.00 target price on Selecta Biosciences and gave the stock a buy rating in a report on Wednesday, July 26th. Zacks Investment Research upgraded Selecta Biosciences from a sell rating to a hold rating in a report on Wednesday, July 12th. Finally, ValuEngine lowered Selecta Biosciences from a hold rating to a sell rating in a report on Tuesday, September 26th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The stock has an average rating of Buy and an average target price of $25.20.

Shares of Selecta Biosciences (NASDAQ:SELB) traded down $0.03 during trading on Thursday, hitting $9.03. The company had a trading volume of 297,600 shares, compared to its average volume of 235,542. The company has a quick ratio of 5.71, a current ratio of 9.48 and a debt-to-equity ratio of 0.32. Selecta Biosciences has a twelve month low of $8.70 and a twelve month high of $28.00.

Selecta Biosciences (NASDAQ:SELB) last announced its quarterly earnings data on Friday, August 11th. The company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.01. Selecta Biosciences had a negative return on equity of 100.06% and a negative net margin of 1,918.59%. The business had revenue of $0.03 million during the quarter. equities research analysts anticipate that Selecta Biosciences will post -2.25 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.watchlistnews.com/selecta-biosciences-inc-selb-cut-to-neutral-at-ubs-ag/1698626.html.

In other news, CFO David Siewers sold 16,424 shares of the company’s stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $20.00, for a total value of $328,480.00. Following the transaction, the chief financial officer now owns 2,194 shares of the company’s stock, valued at $43,880. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Amir Nashat sold 70,226 shares of the company’s stock in a transaction that occurred on Tuesday, September 26th. The shares were sold at an average price of $18.91, for a total value of $1,327,973.66. The disclosure for this sale can be found here. Insiders have sold 355,658 shares of company stock worth $6,955,732 in the last quarter. 41.90% of the stock is currently owned by corporate insiders.

Several institutional investors have recently bought and sold shares of the company. Nationwide Fund Advisors grew its position in shares of Selecta Biosciences by 224.5% in the second quarter. Nationwide Fund Advisors now owns 6,593 shares of the company’s stock valued at $131,000 after purchasing an additional 4,561 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Selecta Biosciences by 1.8% in the third quarter. JPMorgan Chase & Co. now owns 365,138 shares of the company’s stock valued at $7,131,000 after purchasing an additional 6,292 shares during the last quarter. New York State Common Retirement Fund grew its position in shares of Selecta Biosciences by 184.0% in the second quarter. New York State Common Retirement Fund now owns 12,500 shares of the company’s stock valued at $248,000 after purchasing an additional 8,099 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Selecta Biosciences by 26.6% in the third quarter. Bank of New York Mellon Corp now owns 41,020 shares of the company’s stock valued at $748,000 after buying an additional 8,620 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Selecta Biosciences by 827.0% in the second quarter. The Manufacturers Life Insurance Company now owns 11,254 shares of the company’s stock valued at $224,000 after buying an additional 10,040 shares during the period. 53.53% of the stock is currently owned by institutional investors.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

The Fly

Receive News & Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.